Form 4: Eli Lilly Director Acquires Shares via Deferred Compensation

Eli Lilly & Co. Director Juan R. Luciano acquired 18.336 shares of common stock through a deferred compensation plan.

Summary

• Juan R. Luciano, a Director at Eli Lilly & Co. (LLY), acquired 18.336 shares of common stock.
• The transaction occurred on October 20, 2025, at a price of $808.96 per share.
• These shares were acquired as deferred compensation, in lieu of cash, under the Lilly Directors' Deferral Plan.
• The acquired shares will be settled in common stock following Mr. Luciano's separation from service.
• Following this transaction, Mr. Luciano beneficially owns 16,474.296 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director's acquisition of shares, even through deferred compensation, generally signals confidence in the company's long-term prospects and aligns their interests with shareholders. However, the small number of shares and the nature of the acquisition (deferred compensation vs. open market purchase) temper the overall impact.

Positives

• The acquisition of shares by a director, even through deferred compensation, indicates alignment of management's interests with those of shareholders.
• The deferred compensation plan encourages long-term commitment from directors by linking their future compensation to the company's stock performance.

Future Outlook

The acquired shares, deferred as stock units, will be settled in common stock following the reporting person's separation from service, indicating a future conversion event.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects an individual director's compensation structure within the pharmaceutical sector.

Comparison to Industry Standards

• Deferred compensation plans, where directors elect to receive equity in lieu of cash, are a common practice among large publicly traded companies, including those in the pharmaceutical industry, to align director incentives with shareholder value. Companies like Pfizer, Johnson & Johnson, and Merck also utilize similar equity-based compensation structures for their non-employee directors.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The acquired stock units will be settled in shares of common stock following Juan R. Luciano's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Juan R. Luciano, Director, Insider Transaction, Form 4, Deferred Compensation, Stock Acquisition, Pharmaceuticals